Table 2.

Non-small cell lung cancer patient survival following treatment with ICIs and RT.

	Stage II-III NSCLC	Stage IV NSCLC
1-year PFS	56.39% (95% CI: 50.66%-62.03%, I2:39.4%)	—
2-year PFS	43.58%-45%	—
3-year PFS	39.7%	—
4-year PFS	35.0%	—
5-year PFS	33.1%	—
1-year OS	83.25% (95% CI: 79.42%-86.75%, I2:17.6%)	50%
2-year OS	66.16% (95% CI: 62.30%-69.92%, I2:0.0%)	25%
3-year OS	56.7%	—
4-year OS	49.7%	—
5-year OS	42.9%	—

ICIs, Immune checkpoint inhibitors; RT, Radiotherapy; PFS, Progression Free Survival; OS, Overall Survival; NSCLC, non-small cell lung cancer.